

To whom it may concern

Summary attachment justifying the missing results for a trial

EudraCT number: 2016-004578-16
Protocol code: VAL-1221-201-16
Protocol title: A Three-month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 versus Myozyme®/Lumizyme® in Patients with Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment with VAL-1221 in all Patients
Sponsor: Valerion Therapeutics, LLC

The sponsor of this clinical trial has closed several years ago and the development of the IMP is currently discontinued. Therefore, the results of this trial cannot be posted at this time.

Statement issued by: Voisin Consulting, which previously acted as the contact point designated by the sponsor for further information on the trial.

Date: 03 August 2021